EffRx receives FDA approval for BINOSTO to treat osteoporosis

EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO™   (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO™ will be commercially available in the United States in the third quarter of 2012.

Christer Rosen, Chairman & CEO of EffRx states: "We are very pleased to receive this approval from the FDA. BINOSTO™  is a breakthrough innovation for the treatment of osteoporosis, offering those patients who have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy-to-swallow buffered solution."